帕利哌酮与利培酮治疗儿童青少年精神分裂症患者的疗效观察

Efficacy observation of Paliperidone and Risperidone in treatment of children and adolescents with schizophrenia

目的:观察帕利哌酮缓释片与利培酮片治疗儿童青少年精神分裂症患者的疗效观察。方法:将67例首发儿童青少年精神分裂症患者,根据用药不同随机分为帕利哌酮组(32例)和利培酮组(35例)。分别于治疗前及治疗后2、4、8周末用PANSS、PSP和TESS进行评定比较两组患者的治疗效果和不良反应。结果:两组患者的PANSS及PSP评分较治疗前有变化,差异有明显统计学意义(P<0.01);治疗4、8周末,帕利哌酮组患者的PSP评分高于利培酮组,差异有明显统计学意义(P<0.01);两组患者治疗的总有效率无明显差异,帕利哌酮组患者的不良反应少且轻。结论:帕利哌酮缓释片治疗儿童青少年精神分裂症患者的疗效优于利培酮片。

Objective: To observe efficacy of Paliperidone and Risperidone in treatment of children and adolescents patients with schizophrenia. Methods: 67 schizophrenia patients were randomly divided into Paliperidone treatment group( 32) and Risperidone group( 35). All patients were evaluated with positive and negative syndrome scale( PANSS),personal and social performance scale( PSP) and treatment emergent syndrome scale( TESS) before and 2,4,and 8 weeks after the treatment for the efficacy and adverse reactions. Results: After the treatment,there were changes in the scores of PANSS and PSP of the two groups,and there were significant statistical differences before and after the treatment( P < 0. 01). At the 4th and 8th weekends,the score of PSP was significantly higher in Paliperidone group than that in Risperidone group( P < 0. 01). The response rate of Paliperidone was similar to that of Risperidone,but Paliperidone had light side effects. Conclusions: Paliperidone is more effective than Risperidone in the treatment of children and adolescents patients with schizophrenia.